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Introduction. Inflammation and endothelium-derived superoxides are important pathomechanisms in atherothrombotic diseases.
We could previously show that the tyrosine phosphatase SHP-1 acts as a negative regulator in endothelial superoxide production.
In this study we investigated the influence of SHP-1 on platelet-endothelium interaction and arterial thrombosis in TNF𝛼-induced
endothelial inflammation in vivo. Methods. Arteriolar thrombosis and platelet rolling in vivo were investigated in C57BL/6 mice
using intravital microscopy in the dorsal skinfold chamber microcirculation model. Results. Inhibition of SHP-1 by the specific
pharmacological inhibitor sodium stibogluconate did not significantly enhance platelet-endothelium interaction in vivo under
physiological conditions but led to an augmented fraction of rolling platelets in TNF𝛼-induced systemic inflammation. Accordingly,
ferric-chloride-induced arteriolar thrombus formation, which was already increased by SHP-1 inhibition, was further enhanced in
the setting of TNF𝛼-induced inflammation. Platelet aggregation in vitro as well as ex vivo was not influenced by SHP-1-inhibition.
In cultured endothelial cells, sodium stibogluconate increased TNF𝛼-induced surface expression of p-selectin and vonWillebrand
factor. Additionally, TNF𝛼 increased SHP-1 activity and protein expression.Conclusions.The endothelial tyrosine phosphatase SHP-
1 plays an important role for vascular hemostasis in vivo, which is crucial in TNF𝛼-induced endothelial inflammation where it may
serve as an autoinhibitory molecule to prevent excess inflammatory response and thrombus formation.
1. Introduction
Inflammatory processes play a critical role in the devel-
opment of atherosclerosis and its fatal outcomes, such as
myocardial infarction and ischemic stroke [1, 2]. Proinflam-
matory cytokines including TNF𝛼 and IL-1𝛽 contribute to
progression of atherosclerotic plaque size [3, 4]. Translo-
cation of NF-𝜅B, increased production of ROS (reactive
oxygen species), or influence on eNOS expression seem to be
central steps inmediating the inflammatory effects [5–9].The
roles of inflammatory cytokines and ROS in cardiovascular
diseases are inseparably linked, and elevated endothelial-
derived ROS activate proatherogenic signalling pathways and
stimulate vascular smooth muscle cell proliferation [10, 11],
scavenge endothelium-derived nitric oxide, and, thus, aggra-
vate endothelial dysfunction [10, 12]. In addition, platelets
represent an important link between inflammation, athero-
genesis, and thrombosis [13–16]. Platelets can interact with
the activated endothelium [17] and release proinflammatory
cytokines and chemokines stored in 𝛼-granules such as IL-
1𝛽 or CD40L [18], which in turn enhance endothelial inflam-
mation and maintain the vicious circle of inflammation.
2 Mediators of Inflammation
It is not surprising that patients with chronic inflammatory
disorders are at increased risk for cardiovascular morbid-
ity and atherothrombotic events [19], which could not be
explained by traditional cardiovascular risk factors [20–22].
We and others could previously show that systemic admin-
istration of TNF𝛼 mediates prothrombotic effects in vivo
[23, 24], which at least in part are mediated via endothelial
cells.
The SH2-domain containing protein tyrosine phos-
phatase 1 (SHP-1) is known to be a negative regulator of
immune receptor signalling in lymphocytes, macrophages,
and platelets, in which it is typically coactivated upon cellular
stimulation to exert an autoinhibitory function [25–27].Mice
with a defect in the SHP-1 gene (“motheaten viable mice”)
show increased activation of the transcription factor NF-𝜅B
and consecutively elevated levels of inflammatory cytokines
impacting upon the regulation of the immune response [28].
We could previously show that SHP-1 is expressed in vascular
endothelial cells and negatively regulates NAD(P)H-oxidase-
dependent endothelial superoxide production by inhibition
of PI3 K activity and subsequent inactivation of the small
GTPase Rac1; SHP-1 mRNA knockdown as well as inhibition
with the pharmacological inhibitor sodium stibogluconate
leads to oxidative stress in endothelial cells [29].
In this study we investigated the influence of the SHP-1
inhibitor sodium stibogluconate on platelet-endothelium
interaction and arterial thrombosis in TNF𝛼-induced
endothelial inflammation in vivo.
2. Methods
2.1. Chemicals. Murine TNF𝛼 was from Chemicon Inter-
national (USA), human TNF𝛼 from Reliatech (Germany),
collagen was from Nycomed (Germany), and reagents for
multiplate analysis were fromDynabyte (Munich, Germany);
antihuman SHP-1 antibodies (C-19 and D-11) were from
SantaCruz (USA), rabbit anti-humanphospho-SHP-1 (Y564)
antibody was from Abcam (Cambridge, UK), anti-GAPDH
antibody was from Millipore (Billerica, USA), antirabbit
antibody and antimouse secondary antibodies were from
Calbiochem (Darmstadt, Germany) and anti-human vWF-
FITC, Anti-human p-selectin-RPE, and respective negative
controlswere fromAbdSerotec (UK). Sodium stibogluconate
and all other chemicals were from Sigma-Aldrich (Germany).
2.2. Animals. Animal experiments were performed in
wildtype C57BL/6 mice, which were purchased from
Charles River, Sulzfeld, Germany. Surgical procedures
were performed under short-term anesthesia induced by
a single intraperitoneal injection of Midazolam 5mg/kg
(Ratiopharm, Germany), Fentanyl 0.05mg/kg (CuraMED
Pharma, Germany), and Medetomidinehydrochloride
0.5mg/kg (Pfizer, Germany; produced by Orion Pharma,
Finland) diluted in 0.9% NaCl. After the experiments the
animals were killed by injection of an overdose (2 g/kg) of
sodium pentobarbital (Merial, Germany). All experiments
were conducted in accordance with the German animal
protection law and approved by the district government of
Upper Bavaria (approval reference number AZ 55.2-1-54-
2531-162-08). The investigation conforms to the Directive
2010/63/EU of the European Parliament.
2.3. Intravital Microscopy in the Dorsal Skinfold Cham-
ber Microcirculatory Model. The dorsal skinfold chamber
microcirculatory model was used in mice as described
previously [24]. Animals with an intact microcirculation
underwent carotid artery catheterization for application of
drugs or injection of isolated platelets, respectively. Intravital
fluorescence microscopy was performed using a modified
microscope (Zeiss Axiotech Vario, Germany). Images were
recorded with a digital camera (AxioCam HSm, Carl Zeiss
Germany). For all in vivo experimentsmurineTNF𝛼 (Chemi-
con International, USA)was administered via a carotid artery
catheter at a dose of 0.4 𝜇g/kg. This was calculated to match
plasma levels of approximately 5 ng/mL, which caused effects
in vitro. Sodium stibogluconate was infused via the carotid
artery catheter in a dose calculated to match plasmal levels of
approximately 10 𝜇g/mL, as it has been shown to specifically
inhibit SHP-1 in this concentration [30].
2.4. Mouse Platelet Isolation and Staining for In Vivo Studies.
Whole blood was drawn from anesthetized mice by cardiac
puncture. To prevent blood from clotting syringes contained
10% of sodium citrate. The citrated whole blood was spun at
130 g and the obtained PRP was incubated with Carboxyflu-
orescein (CFDA-SE 17𝜇mol/L, Bachem, Switzerland) in the
dark for 30 minutes. Labeled platelets were then spun at
340 g and resuspended in a buffered calcium-free physiologic












5mmol/L D-Glucose, and 5mmol/L Hepes; pH 7.35). For
centrifugation Iloprost (10 ng/mL, Schering, Germany) was
added to prevent platelet activation.The ability of the isolated
and stained platelets to aggregate was tested by platelet
aggregometry.
2.5. Intravital Analysis of Platelet-Vessel-Wall Interaction. For
intravital studies of platelet interaction with the intact vessel
wall isolated and fluorescent-stained murine platelets from
a donor animal were injected via a carotid artery catheter
and observed in the dorsal skinfold chamber model. Movie
sequences of 30 s in 4–6 vessel segments in each animal
were recorded and analyzed using AxioVision Software (Carl
Zeiss, Germany). Vessels with abnormal flow were excluded
from analysis. From the resulting length of the platelet
trace in single images, velocities of single platelets were
calculated using the exposure time of each single picture.
Platelet vessel wall interaction (PVWI) was expressed in
frequency histograms consisting of all platelet velocities
analyzed. Histograms were normalized to the maximum
platelet speed within a vessel to exclude biasing influences of
altered blood flow velocities between different arterioles. As a
consequence a rightward shift in platelet velocity distribution
within a histogram expresses less PVWI, whereas a left-
wards shift signalises increased PVWI at the arteriolar wall.
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Platelets with less than 5% of the velocity of the fastest
platelets were defined as rolling platelets.
2.6. Intravital Assessment of Arteriolar Thrombosis. Intravital
thrombotic vessel occlusion time was assessed in arterioles
of C57BL/6 mice in the dorsal skinfold chamber model.
For induction of intra-arteriolar thrombosis, the ferric chlo-
ride superfusion method was used as described previously
[24]. Before the experiments blood vessel flow was digitally
recorded and regular blood flow was confirmed for all
analyzed arterioles. To visualize vessel lumina before vessel
injury 50 𝜇L of a 5% fluorescein isothiocyanate-labelled
dextran solution (FITC-Dextran, MW 150,000) was infused
via the carotid catheter. Injury to the vascular wall was then
performed by application of 30𝜇L of a ferric chloride solution
(25mmol/L) onto arterioles, using a standardized protocol
and movies were recorded until blood flow ceased.
2.7. Platelet Aggregation Studies. Platelet aggregation in
human platelet-rich plasma (PRP) was measured using the
turbidimetric method described by Born [31]. Human PRP
was obtained by centrifugation of whole citrated blood,
drawn from human cubital veins at 130 g. ADP-, collagen-, or
TRAP-induced platelet aggregationwasmeasured photomet-
rically using a 2-channel aggregometer (ChronoLog 490-2D,
USA) under continuous stirring at 1000 rpm at 37∘C.Written
consent was obtained from platelet donors.
For mice studies blood was collected from the inferior
vena cava in anesthetizedmice with a syringe containing hep-
arin. Whole blood aggregation was performed by impedance
aggregometry with the Multiplate (multiple platelet func-
tion analyzer) assay (Dynabyte, Munich, Germany) accord-
ing to the manufacturer’s protocol. Changes in impedance
expressed as aggregation amplitudes were recorded over 6
minutes in duplicates and results were expressed as mean
arbitrary aggregation units (AU).
2.8. Cell Culture. Human umbilical vein endothelial cells
(HUVECs) and porcine aortic endothelial cells (PAECs)
were isolated as described previously [32] and cultured in
M199 media supplemented with 10% FCS, 10% endothe-
lial growth media (PromoCell, Germany), and 1% peni-
cillin/streptomycin. For all cell culture experiments recom-
binant human TNF𝛼 (Reliatech, Germany) was used. The
procedure was approved by a university ethic review board
and the investigation conforms with the principles outlined
in the Declaration of Helsinki.
2.9. Endothelial Surface Molecule Expression. HUVECs were
grown as described and incubated with sham or recombinant
TNF𝛼 (5 ng/mL) or sodium stibogluconate as indicated. Cells
were stained using anti-p-selectin RPE and anti-vWF FITC
or corresponding RPE- or FITC-labeled negative control. For
measuring a FACSCanto II flow cytometer (Becton Dickin-
son, USA) was used. Data were analyzed using FACSDiva
software (Becton Dickinson).
2.10. Immunoprecipitation of SHP-1 and SHP-1 Activity.
PAECs were washed and lysed in radioimmunoprecipitation
(RIPA) buffer and protein content determined as described
elsewhere [33]. From aliquots of 300𝜇g protein immuno-
precipitations of SHP-1 were performed using a polyclonal
primary anti-SHP-1 mouse antibody (C-19), MACS Pro-
tein G MicroBeads, and MACS separation columns from
Miltenyi Biotec (Bergisch Gladbach, Germany) according
to the manufacturer’s protocol. Equal amounts of SHP-1
were then equilibrated in phosphatase assay buffer (Hepes
20mmol/L, sodium chloride 100mmol/L, magnesium chlo-
ride 5mmol/L, manganese chloride 5mmol/L, pH 6.5). After
addition of 10mmol/L of the chromogenic substrate p-
nitrophenylphosphate and incubation for 1 h (37∘C) solutions
were transferred to multiwell plates, and extinction was
measured at 405 nm (SpectraFluor, Tecan, Germany).
2.11. Western Blot. Protein lysates from PAEC or HUVEC
(whole cell lysate) were prepared and protein content quan-
tified as described elsewhere. Lysates were subjected to
Western blot analysis as previously described [33] and SHP-
1 was detected using a polyclonal rabbit anti-SHP-1 antibody
(C-19). To measure SHP-1 activity phosphorylation of SHP-
1 on Y564 was detected using a rabbit anti-phoshpho-Y564-
SHP-1 antibody (Abcam), as phosphorylation at this site has
been described to correlatewith the phosphatase activity [34].
GAPDH was used as loading control.
2.12. Statistical Analysis. SigmaStat Software was used to
calculate statistical differences. Data were analyzed using
Student’s 𝑡-test or ANOVA for normally distributed variables
or the Mann-Whitney Rank Sum Test or ANOVA on ranks,
when normal distribution was not given. Data are expressed
as means ± SEM. Differences were considered significant
when the error probability level was 𝑃 < 0.05.
3. Results
3.1. Platelet-Endothelium Interaction In Vivo . We assessed
transient interaction of injected labelled platelets to the vessel
wall in vivo by intravital microscopy of vessels in the dorsal
skinfold chamber. Sodium stibogluconate was used in a
concentration of 10𝜇g/mL (11𝜇M), for which it has been
shown to exhibit the by far highest affinity for SHP-1, whereas
10-fold higher concentrations were required to inhibit other
tyrosine phosphatases such as SHP-2 and PTP1B [30].
Systemic treatment with sodium stibogluconate
(10 𝜇g/mL, 30min) did slightly enhance the amount of
rolling platelets under physiological conditions (0.4 ±
0.2% of all analyzed injected platelets versus 0.1 ± 0.1%
without SHP-1 inhibition; 𝑃 = 0.12, 𝑛 = 5) but significantly
elevated rolling platelets in acute systemic inflammation
induced by TNF𝛼 treatment (5 ng/mL, 4 hours; 1.0 ± 0.3%
rolling platelets versus 0.4 ± 0.2% without SHP-1 inhibtion,
𝑃 < 0.05, 𝑛 = 5, Figure 1(a)). Increased transient platelet-
endothelium interaction after SHP-1 inhibition by sodium
stibogluconate in TNF𝛼-induced inflammation is also
indicated by a leftward shift in the platelet flow velocity







































































Figure 1: Inhibition of SHP-1 leads to increased platelet rolling in vivo in TNF𝛼-induced systemic inflammation. (a) In vivo the amount of
rolling platelets (defined as platelets with a velocity of less than 5% of maximal velocity) as analyzed by intravital microscopy in the dorsal
skinfold chamberwas slightly enhanced in vivo after treatmentwith the SHP-1 inhibitor sodium stibogluconate (10 𝜇g/mL, 30min) under basal
conditions but significantly increased in TNF𝛼-induced inflammation (TNF𝛼 5 ng/mL, 4 h). (b) Inhibition of SHP-1 by sodium stibogluconate
in TNF𝛼-induced inflammation resulted in a leftward shift in platelet velocity distribution pattern (i.e., towards lower platelet velocities) in the
frequency histogram, indicating increased transient platelet interaction with the endothelium. The histograms display all platelet velocities
from 5 different animals per group. SG: sodium stibogluconate. ∗Significantly different at 𝑃 < 0.05 (𝑛 = 2900 − 3300 platelets per group from
5 different animals).
histogram (velocities from 2900–3300 analyzed platelets
from 5 different animals in each group, Figure 1(b)). The
maximum platelet velocities in the analyzed vessels as an
approximate measure of flow velocity were not significantly
different between the treatment groups.
3.2. Arteriolar Thrombus Formation In Vivo . To analyze the
effect of SHP-1 inhibtion on thrombus formation in vivo, we
assessed the time to thrombotic arteriolar vessel occlusion
following injury by ferric chloride superfusion to the vascular
wall. The time to complete thrombotic vessel occlusion upon
injury was significantly accelerated from 307 ± 34 s in control
animals to 149 ± 49 s in animals treated with the SHP-1
inhibitor sodium stibogluconate 10 𝜇g/mL for 30 minutes
(𝑛 = 6, 𝑃 < 0.05 versus control animals). Vessel occlusion
time was further accelerated by SHP-1 inhibition in TNF𝛼-
induced (5 ng/mL, 4 hours) inflammation (50 ± 14 s versus
176± 42 s without SHP-1 inhibtion; 𝑛 = 5;𝑃 < 0.05, Figure 2).
3.3. Influence of SHP-1 Inhibtion on Endothelial P-Selectin
and vWF Surface Expression. To better define the relative
contribution of the endothelium to the prothrombotic effects
exerted by SHP-1 inhibtion in TNF𝛼-induced inflamma-
tion we analyzed adhesion molecules relevant to platelet-
endothelium interaction in vitro in primary human endothe-
lial cells (HUVECs) by flow cytometry. First we tested
whether sodium stibogluconate inhibits SHP-1 in endothelial




























Figure 2: Inhibition of SHP-1 leads to accelerated arteriolar throm-
bus formation in vivo. Time to thrombotic arteriolar vessel occlusion
in vivo, as measured in the ferric chloride superfusion model in
the dorsal skinfold chamber in mice, was significantly accelerated
when animals were treated with the SHP-1 inhibitor sodium sti-
bogluconate (10𝜇g/mL, 30min) under basal conditions. TNF𝛼-
induced inflammation itself (TNF𝛼 5 ng/mL, 4 h) led to accelerated
thrombus formation, but the effect was further increased by SHP-
1 inhibition. SG: sodium stibogluconate. ∗Significantly different at
𝑃 < 0.05 (𝑛 = 5-6).
cells and measured SHP-1 activity by the enzymatic pNNP-
dephosphorylation assay. Treatment with sodium stiboglu-
conate (10 𝜇g/mL, 30min) reduced SHP-1 activity in HUVEC
to 58 ± 15% of baseline activity (𝑛 = 7-8, 𝑃 < 0.05,
Figure 3(a)).
P-selectin was not significantly upregulated by the SHP-
1 inhibitor sodium stibogluconate (10𝜇g/mL, 30min) under
basal conditions (120 ± 11% of baseline, 𝑛 = 9–12; 𝑃 =
0.06) but was significantly increased by SHP-1 inhibition in
TNF𝛼-induced (5 ng/mL, 4 hours) inflammation (180 ± 22%
of baseline and 126± 11% of baseline without SHP-1 inhibtion,
𝑛 = 12, 𝑃 < 0.05, Figure 3(b)).
Next we measured vWF on the surface membrane of
HUVEC, which was upregulated by the SHP-1 inhibitor
sodium stibogluconate (10 𝜇g/mL, 30min) already under
basal conditions (124 ± 8% of baseline, 𝑛 = 20, 𝑃 < 0.05)
and showed a tendency to be further increased by SHP-1
inhibtion in TNF𝛼-induced (5 ng/mL, 4 hours) inflammation
(136 ± 13% of baseline versus 121 ± 8% of baseline without
SHP-1 inhibtion, 𝑛 = 9, n.s.; both 𝑃 < 0.05 versus control,
Figure 3(c)).
3.4. Platelet Aggregation. To test for direct effects of the SHP-
1 inhibitor sodium stibogluconate and TNF𝛼 on platelets
we assessed platelet aggregation in vitro in human PRP
using light transmission aggregometry (Born’s method).
Incubation of PRP with human TNF𝛼 5 ng/mL for 4 hours
and additional inhibition of SHP-1 (sodium stibogluconate
10 𝜇g/mL for 30min) did not affect platelet aggregation,
upon stimulation neither with low nor with high doses of
the platelet agonists ADP, collagen, and thrombin-receptor-
activating peptide (TRAP; 𝑛 = 9–12, each, Figure 4(a)).
To test effects of systemic SHP-1 inhibition on platelets
aggregation was measured in whole blood of mice after oral
treatment with sodium stibogluconate, which did not change
ADP-induced (ADP 6.5 𝜇M) platelet aggregation compared
to control treated animals, neither under basal conditions nor
in TNF𝛼-induced inflammation (𝑛 = 6 animals per group,
Figure 4(b)).
3.5. Influence of TNF𝛼 on SHP Activity and Expression. To
investigate whether TNF𝛼 affects SHP-1 phosphatase activity
and protein expression we measured SHP-1 phosphatase
activity by pNPP-dephosphorylation assay and by detection
of SHP-1 phosphorylation at tyrosine 564 by Western blot in
primary endothelial cells (PAEC and HUVEC, resp.).
TNF𝛼 treatment (5 ng/mL) of PAEC caused a rapid
increase of SHP-1 phosphatase activity to 120 ± 6% of baseline
after 3 minutes and 136 ± 14% of baseline after 30 minutes
(𝑛 = 6; 𝑃 < 0.05 versus control, Figure 5(a)) in PAEC.
Similarly, SHP-1 activity was increased by TNF𝛼 treatment
(5 ng/mL for 4 h) in HUVEC (112 ± 2% of baseline, 𝑛 = 4;
𝑃 < 0.05; Figure 5(b)).
SHP-1 protein expression was not changed by TNF𝛼
(5 ng/mL) after 4 hours of stimulation but was significantly
elevated after 24 hours (132 ± 6% of baseline, 𝑛 = 8, 𝑃 < 0.05;
Figure 5(c)).
4. Discussion
In this study we show that inhibition of the tyrosine
phosphatase SHP-1 results in increased platelet-endothelium
interaction and accelerated arteriolar thrombus formation
in vivo, possibly by upregulation of adhesion molecules on
endothelial cells. These effects are further potentiated in
the setting of TNF𝛼-induced inflammation. Since TNF𝛼
augments the activity of SHP-1, the tyrosine phosphatase
may serve as an autoinhibitory feedback mechanism, which
is important to prevent excess inflammatory responses and
thrombus formation.
In our in vivo studies inhibition of treatment with the
SHP-1 inhibitor sodium stibogluconate led to a slightly
greater amount of rolling platelets as compared to control
treated animals under physiological conditions. However,
this effect was significantly increased when SHP-1 was inhib-
ited in an acute inflammatory setting caused by systemic
TNF𝛼 treatment, resulting in significantly elevated transient
platelet-endothelium interaction. When the endothelium is
activated, similar to leukocytes, platelets can roll on the
endothelium [17]. Under shear stress p-selectin and its
counterreceptors PSGL-1 or GPIb and vWF are mediating
platelet interaction with the endothelium and trigger the
release of proinflammatory cytokines and chemokines stored
in 𝛼-granules such as p-selectin or the chemokine-like
factors IL-1𝛽 and CD40L [18] which in turn can activate






















































































Figure 3: Inhibition of SHP-1 increases TNF𝛼-induced upregulation of p-selectin and vWF in endothelial cells in vitro. (a) Incubation of
endothelial cells with the pharmacological SHP-1 inhibitor sodium stibogluconate effectively reduces SHP-1 activity as measured by pNPP-
dephosphorylation assay. (b) Endothelial p-selectin was not changed by sodium stibogluconate under basal conditions but, significantly
upregulated in TNF𝛼-induced endothelial inflammation. (c) vWF was already upregulated by sodium stibogluconate under basal conditions
to a similar level as observed in TNF𝛼-induced endothelial inflammation. SG: sodium stibogluconate. ∗Significantly different at 𝑃 < 0.05
(HUVEC, 𝑛 = 9–12).
the endothelium. Indeed, in vitro in cultured endothelial cells
inhibtion of SHP-1 by sodium stibogluconate led to rapid
upregulation of p-selectin in a TNF𝛼-induced inflammatory
condition, whereas a significant upregulation of vWF was
observed already under basal conditions, which fits very
well in with our in vivo results. These adhesion molecules
have been described to be upregulated by ROS not only
via redox-sensitive transcription factors such as NF-𝜅B [12]
but also by rapid release from Weibel-Palade bodies by a
posttranslational cell signaling responsemediated by not only
classical NADPH oxidase but also by xanthine oxidase [35].
We have previously identified SHP-1 as a negative regulator of
endothelial NADPH-oxidase dependent superoxides already
under basal conditions [29], which highly suggests a role for
ROS to be involved in mediating these effects.
Moreover inhibition of SHP-1 already under basal con-
dition (i.e., without prior stimulation with TNF𝛼) led to a
significantly accelerated thrombotic vessel occlusion time in
vivo in dorsal skin arterioles upon ferric chloride injury.
This effect was even more pronounced in TNF𝛼-induced
inflammation. We have previously shown that TNF𝛼 can
increase arteriolar thrombosis in vivo by several mechanisms
on the transcriptional level including upregulation of tissue
factor, PAI-1, and downregulation of thrombomodulin [24].
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Figure 4: Inhibtion SHP-1 does not affect platelet aggregation in vitro and ex vivo. (a) In platelet-rich plasma (PRP) from healthy human
volunteers SHP-1 inhibition by sodium stibogluconate did not increase platelet aggregation neither under basal conditions nor after
pretreatment with TNF𝛼 (5 ng/mL, 4 h) upon stimulation with the platelet agonists ADP, collagen, or thrombin-receptor activating peptide
(TRAP) in different concentrations (low ADP: 0.5–1 𝜇M; high ADP: 10𝜇M; low collagen: 0.5–4𝜇g/mL; high collagen: 10 𝜇g/mL; low TRAP:
1–1.5𝜇M; high TRAP: 10–14𝜇M; 𝑛 = 9–12, each). (b) Treatment of animals with the SHP-1 inhibitor sodium stibogluconate (10 𝜇g/mL, 30min)
did not affect ADP-induced (6.5 𝜇M) platelet aggregation ex vivo, neither under basal conditions nor in TNF𝛼-induced inflammation (TNF𝛼
5 ng/mL, 4 h, 𝑛 = 6 animals per group). SG: sodium stibogluconate, AU: arbitrary unite.
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Figure 5: TNF𝛼 increases SHP-1 activity and protein expression. (a) TNF𝛼 (5 ng/mL) treatment of endothelial cells increased SHP-1 activity
already within minutes of stimulation as assessed by pNPP-dephosphorylation assay in PAEC (𝑛 = 6–8). (b) This could also be observed
in HUVEC after TNF𝛼 stimulation (5 ng/mL, 4 h) as detected by phosphorylation of SHP-1 at Y564. (c) SHP-1 protein expression was not
changed within the first hours of stimulation but significantly increased after 24 hours of stimulation. ∗Significantly different versus baseline
or as indicated at 𝑃 < 0.05 (𝑛 = 6–8).
Inhibtion of SHP-1 activity for only a short time again
suggests that rapid upregulation of endothelial vWF and p-
selectin, probably involving generation of ROS, is responsible
for the potentiation of TNF𝛼-induced prothrombotic effects.
Elevated expression of vWF on endothelial cells has been
shown to contribute tomicrovascular thrombosis in vivo [36]
and oxidative stress is well described to induce prothrombotic
changes [12].
It should be mentioned, though, that from the thrombus
formation experiment direct effects of SHP-1 inhibition in
platelets cannot be excluded. This is of special interest
especially in the light of a previous study where platelets
isolated from “motheaten viable mice”, which have a defect
in the SHP-1 gene, were hyporesponsive to GPVI stimulation
suggesting a physiological role for SHP-1 in lowering the
threshold for activation by GPVI [27]. In addition, a role for
SHP-1 in the regulation of platelet eNOS has been reported
[37]. To elucidatewhether the observed prothrombotic effects
in vivo could be due to direct effects of SHP-1 inhibition
by sodium stibogluconate in platelets we performed in vitro
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(human PRP) and ex vivo (mouse blood) aggregation studies.
Interestingly, in the concentration where striking effects on
endothelial cells were detected, no changes in platelet aggre-
gation in vitro, neither by sodium stibogluconate itself nor
after prior stimulation with TNF𝛼, compared to untreated
platelets in response to several platelet-activating stimuli such
as collagen, ADP and TRAP could be observed. Similarly,
ex vivo platelet aggregation in mouse whole blood after
treatment with sodium stibogluconate, which caused accel-
erated thrombus formation in vivo, was not affected, neither
under basal conditions nor in TNF𝛼-induced inflammation.
Therefore we conclude that the effects we observed in the in
vivo experiments are due to endothelial mechanisms rather
than direct effects on platelets.
The potentiation of TNF𝛼-induced proinflammatory or
prothrombotic effects by inhibition of SHP-1 activity in
endothelial cells could be explained by an autoinhibitory
feedback mechanism of the phosphatase. Autoinhibitory
functions for SHP-1 have been described in other cell types,
such as lymphocytes, macrophages, and platelets, where the
phosphatase is coactivated and serves as a negative regulator
of immune receptor signaling [25–27]. In this sense we could
previously show that inhibition of SHP-1 in endothelial cells
leads to increased VEGF-dependent superoxide formation
[29]. In bovine aortic endothelial cells, TNF𝛼 has been
shown to activate SHP-1 and inhibit growth factor-mediated
cell proliferation through this mechanism [38]. Accordingly,
Sugano et al. showed that TNF-alpha modulates angiogenic
processes probably by employing SHP-1, as SHP-1 inhibition
increased endothelial cell growth. Interestingly, this was
shown to be caused by an impairment of the ability of TNF𝛼
to block the tyrosine phosphorylation of VEGFR2 induced
by VEGF, strongly suggesting that SHP-1 exhibits a negative
feedback regulation in TNF𝛼 signaling [39]. Several proteins
are tyrosine phosphorylated downstream of TNF-receptor
activation, involving src- and jak-family kinases [40], which
in part have been shown to be regulated by SHP-1 [41]. In
endothelial cells TNF𝛼 caused SHP-1 phosphatase activation
starting already within minutes after stimulation. As SHP-1
inhibition led to prothrombotic changes, which are especially
pronounced in TNF𝛼 induced inflammation, we propose that
activated SHP-1 plays an important autoinhibitory role in
acute TNF𝛼-signaling. Interestingly, protein levels of SHP-
1 in endothelial cells were not significantly elevated after 4
hours of TNF𝛼 stimulation but increased after 24 hours,
suggesting also a function for SHP-1 in chronic inflammatory
processes.
Considering the crucial role of inflammatory cytokines
and oxidative stress in the pathophysiology of cardiovascular
diseases these factors are interesting targets for pharmaco-
logical approaches. Numerous studies targeting inflamma-
tory cytokines by antibodies or ROS by antioxidants have
been performed, which, however, led to conflicting results
regarding a clinical benefit and have not become established
as standard therapy in cardiovascular diseases [42–44]. The
understanding of the pathophysiological processes leading to
cardiovascular diseases is therefore fundamental to develop
new therapeutic strategies. SHP-1 has already been tested as
a therapeutic target in ischemic conditions such as stroke
or myocardial infarction, where inhibition of its activity
resulted in a reduction of infarct sizes [45–47]. Inhibition
of another tyrosine phosphatase, namely PTP1B, resulted
in improvement of peripheral endothelial dysfunction in
heart failure [48]. The cellular effects and functions of the
numerous different cytosolic and membrane-bound tyrosine
phosphatases aremultiple andmany times antagonistic.Thus,
preservation of tyrosine phosphorylation as a therapeutic
principle for vascular medicine, especially using tyrosine
phosphatase inhibitors, must be viewed in a very differenti-
ated manner and evaluated with caution.
5. Conclusion
Our findings indicate that the endothelial tyrosine phos-
phatase SHP-1 plays an important role for vascular hemosta-
sis, which is of great relevance in TNF𝛼-induced endothe-
lial inflammation where it may serve as an autoinhibitory
molecule to prevent excess inflammatory response. Even-
tually decreased SHP-1 activity in an inflammatory setting
increases platelet-endothelium interaction and accelerates
arteriolar thrombus formation in vivo.
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